	Subt. Form P1	O-1449				Number	App	lication Nur	nber		
	INFORMATION DISCLOSURE			BOY Y		479CP	79CP 0		9/965,116		
		IN AN APPL	ICATION		4750)8.577)	oplicant		$-\frac{\pi}{2}$		
				DEC 1	7 2001 밝	•	dimalla		EN T		
	(Us	se several shee	ts if necessary)	_	\$	1 1021					
				2 Presente	Filin	g Date	1 1 4	roup Art Ur	" r		
	Sheet	1	OF	2	Septemb	er 26, 2001	163	1632	- 88		
	U.S. Patent Documents										
	EXAMINER	DOCUMENT		T				FILING	DATE		
•	INITIAL NUMBER		DATE N		NAME	NAME CLASS		SUBCLASS IF APPRO			
ele	(M	5,149,798	09/22/92	Agı	awal et al.	536	27				
			For	oian Pa	tent Docum	onte	 				
	EXAMINER	DOCUMENT		1				TRANS	LATION		
	INITIAL	NUMBER	DATE	C	OUNTRY	CLASS	SUBCLASS	YES	NO		
			Oth on I	<u> </u>	make (I I II II II	A . Al T'a)	D-4- D-4		54- \]		
ele	/ A C1.	VKhorana et al. (1	Otner I 972) "Studies on F		ents (Including		e, Date Perti	nent Pag	es, Etc.)		
ell	C2.	Reese (1978) "T	he Chemical Synth	nesis of Olig	o- and Poly-Nucl	eotides By The F	Phosporotrieste	r Approach	H		
(Resugane et al	3143-3179 (1981) "Deoxynucl	enside Pho	enhoramidites – A	New Class of k	(ev Intermediat	es for			
1	C3.	Deoxypolynucle	otide Synthesis," T	etrahedron	Lett. 22:1859-186	2					
- 1	Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the <i>Eco</i> Rl Recognition Sequence With A Phosphorothioate Group At The Cleavage Site," Biochemistry 23:3443					tion					
- 1	C5.	Agrawal et al. (1	987) "Oligodeoxyn	ucleotise M	ethylphosphonate	s: Synthesis and	d Enzymic Deg	radation,"			
1 .		🤏 i etranearon Let	t. 28(31):3539-354:		enhoroamidates:	Synthosis and B	inding to Polyn	udentides "			
1	C6. Jager et al. (1988) Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides," Biochemistry 27:7237										
- 1	C7. Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus, <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083						ıman				
- 1	C8.	¿ Zon et al. (1991)	"Phosphorothioati	e Oligoncul	eotides" Oligonuc	leotides and Ana	alogues: A Prac	tical Approa	ach pp.		
		Y 87-108	(1992) "Oligonucle	otide Seque	ences Required Fo	or Natural Killer	Cell Activation.	' Jon. J. Ca	ncer Res.		
	C9.	83:1128-1131									
	C10.		An Overview of Pro	ogress in Ar	itisense Therapeu	tics," 8 <i>Antisens</i>	se & Nucl. Acid	Drug Dev.	115-122		
- 1	CRC Press, Boca Raton, Florida C11. Zon (1993) "Protocols for Oliognucleotides and Analogs," <i>Methods in Molecular Biology</i> Vol. 20, pp. 165-189 C12. Prisetsky et al. (1994) "Simulation of Murine Lymphocyte Proliferation By A Phosphorothioate Oligonucleotide W						39				
	C12.	Pisetsky et al. (1	994)"Stimulation o ty For Herpes Simp	f Murine Ly blex Virus."	mphocyte Prolifer 54 <i>Life Sci.</i> 101	ation By A Phos	phorothioate O	ligonucleoti	de With		
}		Yamamoto et al.	(1994) "Lipofectio	n of Synthe	tic Oligodeoxyribo	nucleotide Havi	ng a Palindrom	ic Sequenc	e of		
	C13. AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity," 38 Microbiol. Immu- 831 C14. Agrawal et al. (1995) "Modified Oligonucleotides as Therapeutic and Diagnostic Agents," Curr. Opin. Biotechnol. 19 C15. Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," Nature 371:546-549 Klinman et al. (1996) "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin					mmunoi.					
						nol. 6:12-					
- 1											
- 1						crete Interie	ukin 6,				
- 1		Interieukin 12, and interieron y, 93 Proc. Natr. Acad. Sci. USA 2079 (Liang et al. (1996) "Activation of Human B Cells By Phosphorothicate Oligodeoxynucleotides." J. Clin. Invest.									
- 1	│										
- 1	C18. Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochem. Pharm. 51:173-182										
	C19. Chu et al. (1997) "CpG Oligodeoxynucleotides Act As Adjuvants That Switch On T Helper 1 (Th1) Immunity," 186 J. Exp. Med. 1623										
.1/	XAMINER	7	. 1 0		DATE CONS	IDERED					
W/	1	//7	4 Gus-	And	7	9-3-	-03				
•	EYAMINE	R: Initial if citation is	/ · 971/-		tation is in confor			Line through	h citation		
	if not conform	ance and not consi	dered. Include cop	y with next	communication to	applicant.	., 3 003, Diaw				
	BOSTON 12994		_				yo) (
	20010N 1299	104VI Cm	Ku Le			- 13	1				

INFORMATION DISCLOSURE IN A Applicant (Use several sheets if necessary) BET 17 2001	Subt. Form F	PTO-1449			Dool	CALLE TO THE COLUMN THE COLUMN TO THE COLUMN TO THE COLUMN TO THE COLUMN TO THE COLUMN		
IN AN APPLICATION (Use several sheets if necessary) BEL 17 2001	İ				<u> </u>			
(Use several sheets if necessary DEL 17 2001 Kandimalla Sheet 2 OF 2 Filing Date Group Art Unit- 635 +632 Sheet 2 OF 2 Targeting the Molecular Basis of Disease* (Nature Biotechnology) Confe Cot. Sparwasser et al. (1997) "Antisense 97: Targeting the Molecular Basis of Disease* (Nature Biotechnology) Confe Cot. Sparwasser et al. (1997) "Pattern and Krietics of Orjokine Production Following Administration of Prosphorothicate Organic Indiana Artisense Nucleic Acid Drug. Dev. 495 Cot. Sparwasser et al. (1998) "Octume Edge. Opt DNA is A Potent Enhancer of Systemic and Mucosal Immune Cot. Cot. Sparwasser et al. (1998) "Octume Gage. Opt DNA is A Potent Enhancer of Systemic and Mucosal Immune Cot. Cot. Sparwasser et al. (1998) "Octume Gage. Opt DNA is A Potent Enhancer of Systemic and Mucosal Immune Cot. Cot. Sparwasser et al. (1998) "Octume DNA and Immune Enhancer for Systemic and Mucosal Immune Cot. Cot. Sparwasser et al. (1998) "Octume DNA and Immunostimulatory CpG Oligonucloodides Trigger Maturation and Activation of Murine Dendritio Cotils." 28 Eur. J. Immunol. 2045 Cot. John Latt. (1998) "Octume Cot. 2016 and to the Disposory of Immunostimulatory DNA," 52 Jps. J. Infect. 1991. The World Cot. 2016 and the Disposory of Immunostimulatory DNA," 52 Jps. J. Infect. 1991. The World Cot. 2016 and the Disposory of Immunostimulatory DNA, Sps. Jps. J. Infect. 1991. The World Archivity." Biology. 8 Med. Chem. Lett. 10:1051-1054 Cot. John Cot. 2016 and 1991. The World Cot. 2016 and 1992. The Cot	INF			TP			09/965,	116i
Sheet 2 OF 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		IN AN APPL	LICATION /	(0)	- 2412			<u>_羊</u>
Sheet 2 OF 2 Defined Page 1 (1997) "Antisense 97: Targeting the Molecular Basis of Disease" (Nature Biotechnology) Contect Abstract, pp. 40 C21. Sparwasser et al. (1997) "Macrophagas Sanse Pathogens Via DNA Motifs: Induction of Tumor Necrosis Facilo Mediated Shock," 27 Eur. J. Immunol. 1671 C22. Zhao et al. (1997) "Pattern and Kinelics of Cylokine Production Following Administration of Prosphororbiholate Oilgonucleotdes in Mice," 7 Antisense Nucleic Acid Drug, Dev. 495 C23. McCruskie et al. (1998) "Cuttle Gige. CpC DNA is A Potent Enhancer of Systemic and Mucosal Immunication of Presponses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," J. Immunol. 15:1463-1463-1464-1464-1464-1464-1464-1464-			I	pr.	[]			8
Sheet 2 OF 2 Derivation of the Life of the Control	(L	ise several shee	ets if necessary	DEC 1	7 2001 5	Kanuir	nalia	=
Sheet 2 OF 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				•	Fili	ng Date	Group Ad	F :
Durlord et al. (1997) "Antisense 97: Targeting the Molecular Basis of Disease" (Nature Biotechnology) Confection of Abstract, pp. 40 C21. Spanwasser et al. (1997) "Mecrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor Mediated Shock." 27 Eur. J. Immunol. 1671 C22. Chao et al. (1997) "Pettern and Ninetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleoides in Mediated Shock." 27 Eur. J. Immunol. 1671 C23. McClustive et al. (1998) "Cycling Edge CpG DNA is A Potent Enhancer of Systemic and Mucosal Immune Aesponses Against Heapings in with Influence Vision." Influence Vision States of States Antigen with Influence Vision. Influence	Sheet	2	OF 2	EATA			1.	
C21. Spanwasser et al. (1997) "Mecrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Facto Modelated Shock," 27 Eur. J. Immunol. 1671 C22. Zhao et al. (1997) "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Phosphorothioate Objective Phosphorothioate Objective Phosphorothioate Objectory Phosphorothioate Objectory Phosphorothioate Objectory Phosphorothioate Objectory Phosphorothioate Objectory Phosphorothioate Objectory December 19 (1999) "Store of Chemical Modifications in CpG Containing Phosphorothioate Objectory December 19 (1999) "Store of Phosphorothioate Objectory December 19 (1999) "Store Objective Phosphorothioate Objectory December 19 (1990) "Store Objective Phosphorothioate Objectory December 19 (1990) "Store Objectory December 19 (1990) "Store Objectory December 19 (1990) "Store Objectory Decem		<u> </u>		- 31	Picini	761 20, 2001	1655 4002	
C21. Spanwasser et al. (1997) "Mecrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Facto Modalated Shock." 27 Eur. J. Immund. 1671 C22. Jano et al. (1997) "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Cytokine Production Following Administration of Phosphorothioate Objective State of Phosphorothioate Objectory Activities of Phosphorothioate Objectory Activity of Cytokinaga et al. (1999) "Store of Chemical Modifications in Cyto Containing Phosphorothioate Objectory December 2012" (2013) "Analysis of Chemical Modifications in Cyto Containing Phosphorothioate Objectory December 2014" (2014) "Analysis of Administration Phosphorothioate Objectory December 2014" (2014) "Analysis of Chemical Modifications in Cyto Containing Phosphorothioate Objectory December 2014 (2014) "Analysis of Chemical Modifications in Cyto Containing Phosphorothioate Objectory December 2014" (2014) "Analysis of Chemical Modifications in Cyto Containing Phosphorothioate Objectory December 2014 (2014) "Analysis of Chemical Modification of a Single Decrypructeoside," Biocry, & Med. Chem. Lett. 10:1051-1054 C28. Agrawal et al. (2000) "Immunostimulatory Activity of Cyto Containing Phosphorothioate Objectory Decryption 2014" (2014) "Analysis of Chemical Modification of a Single Decrypructeoside," Biocry, & Med. Chem. Lett. 10:1051-1054 CXAMINER Initial if citation is cooperated and an activity of Cyto Containing Phosphorothioate Objectory Decryption 2014 (2014) "Analysis of Chemical Modification of a Single Decryption 2014" (2014) "Analysis of Chemical Modification of a Single Decryption 2014" (2014) "Analysis of Chemical Modification 2014" (2014) "Analysis o	C20	Dunford et al. (1	997) "Antisense 97: 1	argeting	the Molecular Ba	asis of Disease" (Note	ra Piatachaelas I	<u> </u>
C22. Zhao et al. (1997) "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Citigonucleodaes in Mice." "J. Antiseases Nucleic Acid Drug. Dev. 195" C23. McCluskie et al. (1998) "Cutting Edge- Cp6 DNA is A Potent Enhancer of Systemic and Mucosal Immune Responses Air Hepatitis 8 Surface Antigen with Intranasal Administration to Mice." J. Immunol. 161:4463. C24. Moldoveanu et al. (1998) "Op6 DNA, a Novue Immune Enhancer for Systemic and Mucosal With Intranasal Administration to Mice." J. Immunol. 161:4463. C35. Sparwasser et al. (1998) "Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Murine Dondritic Cells," 28 Eur. J. Immunol. 2045 C36. Jokunaga et al. (1998) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bloog. & Med. Chem. Lett. 10:1051-1054 EXAMINER DATE CONSIDERED DATE CONSIDERED P3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	7							
C22. Zhao et al. (1997) "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Citigonucleodaes in Mice." "J. Antiseases Nucleic Acid Drug. Dev. 195" C23. McCluskie et al. (1998) "Cutting Edge- Cp6 DNA is A Potent Enhancer of Systemic and Mucosal Immune Responses Air Hepatitis 8 Surface Antigen with Intranasal Administration to Mice." J. Immunol. 161:4463. C24. Moldoveanu et al. (1998) "Op6 DNA, a Novue Immune Enhancer for Systemic and Mucosal With Intranasal Administration to Mice." J. Immunol. 161:4463. C35. Sparwasser et al. (1998) "Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Murine Dondritic Cells," 28 Eur. J. Immunol. 2045 C36. Jokunaga et al. (1998) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bloog. & Med. Chem. Lett. 10:1051-1054 EXAMINER DATE CONSIDERED DATE CONSIDERED P3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	C21	Mediated Shock	J. (1997) "Macrophag ." 27 Fut J. Immunol	es Sense	Pathogens Via	DNA Motifs: Induction	of Tumor Necrosis	Factor-α
C23. McCluskie et al. (1998) *Cutting Edge: CpG DNA is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intransasi Administration to Mice; *J. Immunol. 161:4463. C24. Molcoveanu et al. (1998) *CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunication With Influenza Virus; *Vaccine 16:1216-1224 C25. *Sparwasser et al. (1998) *Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Murine Dendritic Cells; *28 Eur. J. Immunol. 2045 C26. *Tokunaga et al. (1999) *Site of Chemical Modifications in CpG Containing Phosphorotinicate Oligodeoxynucleotide Modulates Is Immunostimulatory Activity. *Bioorg. & Med. Chem. Lett. 9:3453-3458 C27. *Agrawal et al. (2000) *Antisense Therapeutics: Is It As Simple As Complementary Base Recognition, *6 Mol. Modulates Is Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside, *Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER **Maturation** DATE CONSIDERED P. 3-03	C22	/Zhao et al. (1997	7) "Pattern and Kineti	cs of Cyto	kine Production	Enllaude - Adult 1	tion of Phonehomati	
C24 Mildoveanu et al. (1999) CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Vrus, Vaccine 16:1216-1224 C25 Sparwasser et al. (1999) Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and ACtivation of Murine Dendritic Cells, "26 Eur. J. Immunol. 2045 C26, Tokunaga et al. (1999) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity Bloorg. & Med. Chem. Lett. 3:3453-3458 C28. Agrawal et al. (2000) "Antisense Therapeutics: Is it As Simple As Complementary Base Recognition," 6 Mol. Modulated by Modification of a Single Deoxynucleoside," Bloorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER Maturation of Assistance of Constitution of Constitution of Assistance of Constitution of	H	Oligonucleotides	in Mice," 7 Antisens	e Nucleic	Acid Drug. Dev.	495_	lion of Phosphorothi	oate
C25. Sparwasser et al. (1999) "Bacterial DNA and Immunostimulatory CpG Oligonuciotides Trigger Maturation and Activation of Murine Dendritic Cells," 28 Eur. J. Immunol. 2045 C26. Tokunaga et al. (1999) "How BCG Led to the Discovery of Immunostimulatory DNA," 52 Jap. J. Infect. Dis. 1 C27. Tokunaga et al. (1999) "How BCG Led to the Discovery of Immunostimulatory DNA," 52 Jap. J. Infect. Dis. 1 C28. Tokunaga et al. (1999) "How BCG Led to the Discovery of Immunostimulatory DNA," 52 Jap. J. Infect. Dis. 1 C29. Agrawal et al. (2000) "Amisense Therapeutics: Is it As Simple As Complementary Base Recognition," 6 Mol. M. Agrawal et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER Juitial if citation is consultative and an analysis of the Consultation of the Consulta	C23							
C25. Sparwasser et al. (1999) "Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Mulnim Bondritic Cells," 28 Eur. J. Immunol. 2045 C28. Tokunaga et al. (1999) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity," Biong. & Mad. Chem. Lett. 9:345-3458 C28. Agrawal et al. (2000) "Antisense Therapeutics: Is it As Simple As Complementary Base Recognition," 6 Mol. M. 70day 72 C29. Zhao et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER DATE CONSIDERED DATE CONSIDERED 9-3-03	C24				nmune Enhance	er for Systemic and M	e," J. Immunol. 161:	4463-44
C26. Tokunaga et al. (1999) "How BCG Led to the Discovery of Immunostimulatory DNA," 52 Jap. J. Infect. Dis. 1 C27. Zhac et al. (1999) "Site of Chemical Modifications in CpG Containing Phosphorothicate Oligodeoxynucleotide Modulates its Immunostimulatory Activity," Biology & Med. Chem. Lett. 9:3453-3458 C28. Agrawal et al. (2000) "Antisense Therapeutics: Is it As Simple As Complementary Base Recognition," 6 Mol. M. Today 72. Zhao et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER Date of Chem. Lett. 10:1051-1054 DATE CONSIDERED P. 3-03 DATE CONSIDERED P. 3-03								
C22. / Counaga et al. (1999) 'How BGG Led to the Discovery of immunostimulatory DNA,' 52 Jap. J. Infect. Dis. 1 C27. / Photo et al. (1999) 'Ele of Chemical Modifications in CpG Containing Phosphorothicate Oligodeoxynucleotide C28. / Agrawal et al. (2000) 'Antisense Therapeutics: Is It As Simple As Complementary Base Recognition," 6 Mol. M Today 72 C29. Zhao et al. (2000) 'Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER Initial if citation is consisted than the containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054	C25.	ACtivation of Mu	rine Dendritic Cells." :	NA and IIT 28 <i>Fur .I</i>	munostimulator	y CpG Oligonucleotid	es Trigger Maturatio	n and
Modulates Its Immunostimulatory Activity," Bloorg. & Med. Chem. Lett. 9:3453-3458 C28. Agrawal et al. (2000) "Antisense Therapeutics: Is It As Simple As Complementary Base Recognition," 6 Med. M. M. Today 72. Zhao et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER DATE CONSIDERED 9-3-03	C26,	. 🖊 / okunada et al. ((1999) "How BCG Led	to the Di	convenied Immi	nostimulatory DNA "	52 Jan J Infect Di	
C28. Agrawal et al. (2000) "Antisense Therapeutics: Is it As Simple As Complementary Base Recognition," 6 Mol. M 70day 72 C29. Zhao et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 EXAMINER DATE CONSIDERED 9-3-03	C27.						ate Oligodeoxynucle	otide
C29. Zhao et al. (2000) "immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 C29. Aminor of the Control of the Cont	Can							
EXAMINER AND AND DATE CONSIDERED 9-3-03	1 020.	Today 72		-poulos. 1	a it wa aitiibia W	s complementary Ba	se Hecognition," 6 A	fol. Med.
EXAMINER Met Jan Ford Date Considered 9-3-03	C29.	Zhao et al. (2000)) "Immunostimulatory	Activity of	f CpG Containin	g Phosphorothioate (Oligodeoxynucleotide	e is
EXAMINED Initial if citation is considered upperbor or not site in a few size in the size		Woodsiated by Will	dification of a Single	Deoxynuc	leoside," Bioorg	. & Med. Chem. Lett.	10:1051-1054	
EXAMINED Initial if citation is considered upperbor or not electrical in the considered and a second								
EXAMINED Initial if citation is considered upperbor or not site in a few size in the size								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th		-						
EXAMINED Initial if citation is considered upperbor or not site in a few size in the size								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								-
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINED Initial if citation is considered unbetter or not situation in								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th								
EXAMINED Initial if citation is considered unbetter or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								
EXAMINER Initial if citation is considered unbelow or not situation in								 .
EXAMINED Initial if citation is considered unbetter or not situation in								
EXAMINED Initial if citation is considered upperhase and site is a second part of the considered in th	- - 							
EXAMINED Initial if citation is considered upperbor or not site in a few size in the size								
EXAMINED Initial if citation is considered upperbor or not site in a few size in the size	EXAMINER	1			B			
EXAMINED Initial if citation is considered unother or not site in the initial in the initial in the initial in the initial ini		// 4./	1	,	DATE CONSID	ERED		
EXAMINER Initial if citation is constant unother or not site in the		Morel 7.	Shann to	d	9	-3-17		
A THE PROPERTY OF THE PROPERTY	EXAMINER!	initial if citation is co	nsidered whether or	not citatio	n ie in coefe-	non with 14555 a c		
f not conformance and not considered lactude copy with next communication to applicant.	not conforman	ce and not consider	ed laclude conv with	next com	munication to ~~	ince with MPEP § 609	9: Draw Line through	citation

"Imily the

6/30/04

Subt. Form P1	TO 1440	-							
			101A		Z-479CP	Apr	plication Nur	TEC OF	
SUPP	PLEMENTAL		MATION .	(Y)	Z-479CP (508.577)		9/905, 1-	一一子	*** ***
	DISCLO		FED U 1 2	m 8		Applicant		- '	IVE
	IN AN APPL	LICATIO	FEB 0 1 200	(A) &		ndimalla		EED A F	-
a i	se several sheel	\" # 7300	魔	A.				LER 0 12	2002
(00	ie severai siico	its if neces	RADENAR	1 to Ell	iling Date		Group Art Ur	MUCIVIER 16	
Sheet	1	OF	1	Cantem	0E 200		1000	טרואובט ונ	600/2
		T	1	2shreiiir	ber 26, 2001	1	1632		
			IIS Pat	ent Docume					
EXAMINER	DOCUMENT	DAT				T	FILING	DATE	
INITIAL	NUMBER	DATE	<u> </u>	NAME	CLASS	SUBCLASS	IF APPRO	OPRIATE	
	<u> </u>								
			Foreign Pr	atent Docum					
EXAMINER	DOCUMENT					т —	TRANC	17/041	
INITIAL	NUMBER	DATE	<u>:</u>	COUNTRY	CLASS	SUBCLASS	TRANSL YES	LATION NO	
ll	WO 99/62923	† <u> </u>		PCT	+	 	120	NO	
	10				+		 		
		Otr	ner Docume	ents (Includir	ng Author, Title	e. Date Perti	nent Page	as. Etc.)	
 '								<u>,, _</u>	
								Z_{\parallel}	
							_		
<u> </u>						-/			
						/			
	 								
'					/				
								-	
			<i></i>						
		$\overline{}$							
									
									
	/								
			_						
XAMINER		`		DATE CONS	IDERED				
KAMINER (6	<u> </u>		DATE CONS	SIDERED				

BOSTON 1319148v1

SHEET	1	OF	1

Subt. Form PTC-1449

SUPPLEMENTAL INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

EY6-005US2

Application Number

09/965,116

Applicant

Filing Date

Kandimalla et al.

Group Art Unit

11-

9/26/01

-1632 /635

		U.	S. PATENT [OCUMENTS	5		
EXAMINER INITIAL	IDENTIFIER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		•	,- [Ħ	-0
						-05	MED
						REUL	
						at 1	8 500x
						000	70000
						-	TER 160012900
						TECH CE	dir.
	<u> </u>	F001	TICN DATEN	TOOCHMEN	ITC	150	•

EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ſ	EXAMINER	IDENTIFIER	
٥.	INITIAL		A I A at Martinessa Thermouties" Curr Onin Chem Biol 2:510 528 1008
de	\mathcal{H}	C1	Agrawal et al., "Antisense Therapeutics", Curr. Opin. Chem. Biol., 2:519-528, 1998.
1		C2	Chaix et al., "3'-3' Linkied Oligonucleotides: Synthesis and Stability Studies", Bioorganic & Medicinal Chemistry Letters, 6:827-832, 1996.
	* .	C3	Klinman, Dennis M., "Therapeutic Applications of CpG-Containing Oligodeoxynucleotides", Antisense & Nucleic Acid Drug Development, 8:181-184, 1998.
		C4	Yu et al., "Accessible 5'-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity", <i>Bioorganic & Medicinal Chemistry Letters</i> , 10: 2585-2588, 2000.
		C5	Kandimalla et al., "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships", <i>Bioorganic & Medicinal Chemistry</i> , 9:807-813, 2001.
Ŋ	(h	C6	International Search Report in connection with Patent Cooperation Treaty Application No. PCT/US01/30137.

fruit 1. Ggs Food

9-2-03